Colorectal Cancer New Reference: Encorafenib, Cetuximab, Chemotherapy in bRAF Mutant Colorectal Cancer Ulas D. Bayraktar, MD 2025-03-31
Bladder Cancer New Indication: Adjuvant Pembrolizumab for Bladder Cancer Ulas D. Bayraktar, MD 2025-03-31
Non-Small Cell Lung Cancer New Indication: Datopotamab Deruxtecan in NSCLC with Actionable Mutations Ulas D. Bayraktar, MD 2025-03-31
Neuroendocrine Carcinoma New Indication: Cabozantinib for Advanced Neuroendocrine Tumors Ulas D. Bayraktar, MD 2025-03-28
Non-Small Cell Lung Cancer New Drug: Ivonescimab for PD-L1 Positive NSCLC Ulas D. Bayraktar, MD 2025-03-14
Skeletal Sarcoma New Drug: Vimseltinib for Tenosynovial Giant Cell Tumor Ulas D. Bayraktar, MD 2025-03-14
Chronic Lymphocytic Leukemia New Reference: Zanubrutinib for Treatment-Naive CLL Ulas D. Bayraktar, MD 2025-03-14
Mantle cell lymphoma New Indication: Ibrutinib with Venetoclax for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2025-03-02
Non-Small Cell Lung Cancer New Protocol: Osimertinib with Ramucirumab for EGFR-Mutated NSCLC Ulas D. Bayraktar, MD 2025-03-02
Hepatocellular Carcinoma New Reference: Lenvatinib and Pembrolizumab for HCC Ulas D. Bayraktar, MD 2025-03-02
